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ABSTRACT
Although lung volume reduction surgery improves
survival in selected patients with emphysema, there has
been ongoing interest in developing and evaluating
bronchoscopic approaches to try to reduce lung volumes
with less morbidity and mortality. The placement of
endobronchial valves is one such technique, and
although some patients have had a signiﬁcant
improvement, responses have been inconsistent because
collateral ventilation prevents lobar atelectasis. We
describe the protocol of a trial (ISRCTN04761234) aimed
to show that a responder phenotype, patients with
heterogeneous emphysema and intact interlobar ﬁssures
on CT scanning, can be identiﬁed prospectively, leading
to a consistent beneﬁt in clinical practice.
BACKGROUND
Despite optimal pharmacological therapy and pul-
monary rehabilitation, patients with COPD remain
signiﬁcantly disabled. Emphysema, the destruction
of lung parenchyma, is an important feature of the
disease. Loss of lung elastic recoil leads to airﬂow
obstruction, gas trapping and increased operating
lung volumes. Where the condition is heteroge-
neous, the worst affected areas of lung expand dis-
proportionately, restricting the ventilation of
relatively more healthy areas. Lung volume reduc-
tion surgery (LVRS) to resect these areas has been
clearly shown to improve outcomes in selected
patient groups.1 However, this surgical intervention
is associated with signiﬁcant morbidity and an early
mortality rate of about 5% was reported in the
NETT trial, though this is likely to be lower in
current practice.2 There is, therefore, considerable
interest in developing novel treatment approaches
that can reduce lung volumes and gas trapping,
either more safely than LVRS, or else in patients
for whom LVRS is not an option.
One such approach is bronchoscopic lung
volume reduction (BLVR); the placement of endo-
bronchial valves using a ﬁbreoptic bronchoscope,
to allow air to leave but not enter emphysematous
areas of the lung, causing them to collapse. In het-
erogeneous disease this allows the relatively health-
ier lung to function better by diverting air to more
perfused areas and recruiting prior ‘compressed’
alveoli. Initial pilot work by our group and
others was encouraging, demonstrating that valve
placement could reduce dynamic hyperinﬂation,
improving exercise capacity in association with
improvements in inspiratory capacity and gas
transfer.3 Moreover, follow-up of an early cohort
showed that all patients in whom radiological
atelectasis had occurred (n=5) were alive 6 years
post- procedure, whereas, 8 of the 14 without
radiological atelectasis had died.4 This raised
the possibility that BLVR may, like LVRS, offer a
survival advantage in appropriately selected
patients.
The large multicentre prospective study
(Endobronchial Valve for Emphysema Palliation
Trial (VENT)) aimed to determine the effectiveness
of unilateral endobronchial valves compared to
standard medical treatment with coprimary end-
point of forced expiratory volume in 1 s (FEV1)
and 6 min walk distance (6MWD) at 6 months.5
Over an 18-month period, 321 patients were ran-
domised (2:1) to either unilateral lobar valves
(n=220) or standard medical care (n=101). The
protocol did not blind the patients or assessors to
the allocation of treatment, and no sham proce-
dures were carried out and, therefore, a degree of
placebo effect cannot be ruled out. The study
achieved statistically but not clinically signiﬁcant
improvements in primary endpoints; a 6.85% dif-
ference in FEV1 and 5.7% difference in 6MWD
between treatment and control groups at 6 months.
As the effect size overall was small, it was consid-
ered insufﬁcient for approval by the US Food and
Drug Administration. However, a posthoc analysis
identiﬁed a subgroup of responders: patients with
high heterogeneity and intact interlobar ﬁssures. At
12-month follow-up, 17.9% improvement was seen
in FEV1 if ﬁssures were intact compared to 2.8% if
ﬁssures were incomplete. Additionally, patients
with the greatest degree of heterogeneity on com-
puterised tomography (CT) had signiﬁcantly
greater improvement in FEV1 and 6MWD.
These results conﬁrmed the concept of ‘lobar
exclusion’ where beneﬁt from endobronchial valve
placement is greatest when air is prevented from
entering the target lobe by occlusion of anatomical
airways and by the absence of abnormal collateral
ventilation through pathological gaps in interlobar
ﬁssures.
Based on these data and evidence for a survival
beneﬁt where radiological atelectasis occurred, we
obtained funding from the UK National Institute
for Health Research (NIHR) efﬁcacy and
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mechanisms evaluation (EME) scheme to conduct a randomised,
double-blind placebo-controlled trial of endobronchial valve
placement in patients with COPD, the BeLieVeR-HIFi study
(BLVR for patients with high heterogeneity and intact ﬁssures).
This is the ﬁrst implantable device study to have been funded by
the EME programme.
STUDY DESIGN
The BeLieVeR-HIFi study aims to prospectively select stable,
severe (GOLD III or IV) COPD patients with hyperinﬂation
(TLC>100% and RV>150%) with a limited exercise capacity
6MWD <450 m despite optimal medical therapy (ﬁgure 1).
The full protocol is available as an online supplement. Patients
will be identiﬁed through a COPD multidisciplinary team
meeting including chest physicians, surgeons and radiologists.
CT thorax must demonstrate heterogeneous emphysema with a
deﬁned target lobe with lung destruction and intact adjacent
interlobar ﬁssures. Scans will be reviewed by two radiologists
independently, and a third will adjudicate on any disagreements.
Radiologists will have to agree that the worst affected lobe of
the lung has an emphysema score of >2 (according to the
NETT study scoring system),1 that it is at least 1 point higher
than ipsilateral lobes and that it has >90% intact ﬁssures visible
on at least one projection. Exclusion criteria will be (1) signiﬁ-
cant comorbidity which limits exercise capacity or prognosis,
(2) signiﬁcant daily sputum production, (3) Hypoxia
(ie, PaO2<6.5 kPa breathing air). Lower limits for lung function
were not otherwise formally deﬁned, but patients were excluded
if they were considered clinically to be too limited or frail to
undergo bronchoscopy or to tolerate a pneumothorax.
Study participants will be randomised either to undergo uni-
lateral lobar endobronchial valve placement aiming to achieve
lobar atelectasis, or in the control group, to bronchoscopy and
‘sham’ valve placement. Although target lobe selection will be
based on CTappearances alone, measurements of collateral ven-
tilation using the Chartis system will also be made.3 This
bronchoscopic system uses a balloon to occlude the target
airway. If continuing ﬂow is identiﬁed, this is taken to indicate
collateral ventilation ‘CV positive’. Although associated with the
occurrence of atelectasis in case series, it is not possible to
Figure 1 Flow diagram for the
BeLieVeR-HIFi study.
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obtain meaningful measurements in a signiﬁcant proportion of
patients.
OUTCOME MEASURES
The primary endpoint will be the percentage change in post-
bronchodilator FEV1 measured 90 days postprocedure. This has
been selected as the primary endpoint as it is the measure most
usually accepted by regulatory authorities. Plethysmographic
lung volumes and carbon monoxide transfer factor will also be
measured. It is expected that improvement in lung function in
patients with BLVR will be accompanied by reductions in lung
volumes and possibly increases in transfer factor. Other out-
comes will include health-related quality of life (COPD assess-
ment test (CAT) score and the EQ5D), as well as change in
endurance time on cycle ergometry at 70% baseline peak work-
load exercise capacity.
Outcomes will be assessed at 90 days after treatment by trial
staff blind to treatment allocation. The purpose of the study is
to assess whether the ‘responder’ phenotype can be identiﬁed
prospectively. After 90 days, the trial ends and patients will be
offered a range of options on a clinical basis including, as appro-
priate, LVRS or open-label valves in control subjects who were
CV negative. We included LVRS as a treatment option as there is
a considerable overlap between candidates for BLVR and LVRS,
and the latter has a strong evidence base including for improved
survival.1 Additionally, a pragmatic approach in the future is
likely to involve using BLVR as a way to avoid or delay the need
for LVRS.
A key issue will be around safety. The main safety analysis will
be the occurrence of adverse events in the ﬁrst 3 months, in par-
ticular exacerbations, hospital admissions and pneumothorax.
However, longer-term safety data will be collected for at least
5 years. In trials of BLVR, to date, the reported rate of pneumo-
thorax has been about 1%. However, as patient selection
improves and with it the frequency with which lobar atelectasis
increases, pneumothoraces will also occur more often, as this
complication is driven by changes in lung volumes. Patients
selected for BLVR must not have such severe disease that they
would be unlikely to survive a pneumothorax if it occurs, and
this challenges the idea that BLVR is necessarily an option for
patients whose COPD is too severe for LVRS to be considered.
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